IDEAYA Biosciences 향후 성장

Future 기준 점검 2/6

IDEAYA Biosciences (는) 각각 연간 21.6% 및 31.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -28.2% 로 예상됩니다.

핵심 정보

21.6%

이익 성장률

19.93%

EPS 성장률

Biotechs 이익 성장	23.0%
매출 성장률	31.1%
향후 자기자본이익률	-28.17%
애널리스트 커버리지	Good
마지막 업데이트	12 Dec 2025

최근 향후 성장 업데이트

Recent updates

Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away

Nov 25

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Jul 28

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Apr 16

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 04

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Sep 20

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Jul 08

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Jun 18

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Feb 22

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Feb 16

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03

이익 및 매출 성장 예측

NasdaqGS:IDYA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	264	-235	-217	-114	10
12/31/2027	143	-303	-253	-203	16
12/31/2026	50	-330	-309	-287	19
12/31/2025	217	-111	-45	-14	18
9/30/2025	215	-161	-105	-102	N/A
6/30/2025	7	-332	-297	-294	N/A
3/31/2025	7	-307	-268	-264	N/A
12/31/2024	7	-274	-251	-248	N/A
9/30/2024	4	-178	-153	-150	N/A
6/30/2024	12	-154	-134	-131	N/A
3/31/2024	16	-129	-135	-131	N/A
12/31/2023	23	-113	-118	-115	N/A
9/30/2023	23	-103	-116	-115	N/A
6/30/2023	45	-74	-111	-109	N/A
3/31/2023	47	-68	-98	-95	N/A
12/31/2022	51	-59	-91	-87	N/A
9/30/2022	50	-53	-85	-80	N/A
6/30/2022	29	-66	-72	-69	N/A
3/31/2022	32	-55	-64	-62	N/A
12/31/2021	28	-50	-58	-56	N/A
9/30/2021	36	-37	-53	-51	N/A
6/30/2021	36	-30	50	52	N/A
3/31/2021	27	-31	50	51	N/A
12/31/2020	20	-34	55	55	N/A
9/30/2020	9	-40	58	58	N/A
6/30/2020	N/A	-46	-43	-42	N/A
3/31/2020	N/A	-44	-40	-39	N/A
12/31/2019	N/A	-42	-41	-39	N/A
9/30/2019	N/A	-40	-40	-38	N/A
6/30/2019	N/A	-42	N/A	-36	N/A
3/31/2019	N/A	-38	N/A	-32	N/A
12/31/2018	N/A	-34	N/A	-28	N/A

애널리스트 향후 성장 전망

수입 대 저축률: IDYA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: IDYA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: IDYA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: IDYA 의 수익(연간 31.1%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: IDYA 의 수익(연간 31.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: IDYA는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/04 16:59
종가	2026/01/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

IDEAYA Biosciences, Inc.는 33명의 분석가가 다루고 있습니다. 이 중 19명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Madhu Kumar	Baird
Zhiqiang Shu	Berenberg
Suranjit Mukherjee	BTIG

IDEAYA Biosciences 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus revenue estimates increase by 242%

Consensus revenue estimates increase by 501%

Consensus revenue estimates fall by 32%

Price target decreased by 8.1% to US$46.93

Consensus revenue estimates increase by 22%

Consensus revenue estimates decrease by 53%, EPS upgraded

Recent updates

Insufficient new directors

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (Optimum-02) of Darovasertib in Combination with Crizotinib in First-Line HLA A2-Negative Metastatic Uveal Melanoma

IDE034, a Bispecific ADC Licensed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd to IDEAYA Biosciences, Inc, Receives FDA IND Clearance

Ideaya Biosciences, Inc. Announces Ind Clearance for Ide034, A Potential First-In-Class Bispecific B7h3/Ptk7 Top1 Adc Targeting Multiple Solid Tumor Types

Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 242%

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in A Proffered Paper Oral Presentation At ESMO 2025

IDEAYA Biosciences Announces Positive Data from Phase 1/2 Combination Trial of IDE397, a Potential First-In-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397

Consensus revenue estimates increase by 501%

IDEAYA Biosciences, Inc. Announces IND Submission for IDE892, A Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Ideaya Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma At the 2025 Society for Melanoma Research Congress

Consensus revenue estimates fall by 32%

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

IDEAYA Biosciences, Inc. Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

Price target decreased by 8.1% to US$46.93

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000 Growth Index

Ideaya Biosciences, Inc. Appoints Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences, Inc., Annual General Meeting, Jun 24, 2025

Insufficient new directors

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

Consensus revenue estimates increase by 22%

IDEAYA Biosciences, Inc. Announces Resignation of Susan L. Kelley from the Board

IDEAYA Biosciences, Inc. Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

President exercised options to buy US$278k worth of stock.

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ideaya Biosciences, Inc. Announces the Appointment of Joshua Bleharski as Chief Financial Officer

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

Consensus revenue estimates decrease by 53%, EPS upgraded

Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

Consensus revenue estimates fall by 32%

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

Consensus revenue estimates increase by 10%

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

Chief Legal Officer & Company Secretary exercised options to buy US$1.9m worth of stock.

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

Chief Scientific Officer notifies of intention to sell stock

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

President notifies of intention to sell stock

Consensus revenue estimates fall by 28%

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Price target increased by 12% to US$49.11

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Principal Accounting Officer notifies of intention to sell stock

Price target increased by 8.2% to US$43.70

Co-Founder notifies of intention to sell stock